Autoantibodies spectrum in HCV and HBV infected patients
More details
Hide details
Department of Virology, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland
Department of Hepatology and Acquired Immunodeficiencies, Warsaw Medical University, Warsaw, Poland
Joanna Cielecka-Kuszyk   

Department of Virology, National Institute of Public Health, National Institute of Hygiene, Warsaw, Poland
J Pre Clin Clin Res. 2013;7(2):114–117
Hepatitis B and C viruses have the potential for generating autoimmune processes with dysregulation of the cytokines, Th1 chemokines and molecular or epitope mimicry between self-antigens and viral proteins. These phenomena include the production of autoantibodies, but their clinical significance is still unknown. The aim of this study was to determine the presence of autoantibodies in HCV compared to HBV infected patients, and to find the association of their presence with the age, sex and microscopical changes in the liver. The incidence of autoantibodies presence parallel to the liver biopsy was assessed in 363 consecutive patients with hepatitis C, and 71 patients with hepatitis B. It was found that 66 (18%) HCV and 8 (11%) HBV infected patients had positive results. Pathomorphological changes typical for autoimmune hepatitis were not found in this group of patients with viral infection. The HCV infected patients with autoantibodies were significantly older than patients without autoantibodies. This correlation could be connected with the orsening of the self-mechanisms protecting against autoimmune reactions and the longer duration specially of HCV infection. No such similar correlation was observed in the group of HBV infected patients.
National Institutes of Health National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C. Hepatology 2002; 36: 3–20
World Health Organization. Hepatitis C Fact. 2012, sheet No 164 www. (access: 2013.07.23).
Alter HJ, Seeff LB. Recovery, persistence and sequelae in hepatitis c virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000; 20: 17–35.
Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Ann Rev Pathol. 2006; 1: 23–61.
Oldstone MB. Molecular mimicry and immune-mediated diseases.FASEB J. 1998; 12: 1255–1259.
Zignero AL, De Carli M, Monti M, Careccia G, La Villa G, Gainnini C et al. Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. J Med Virol. 1995; 47: 58–63.
Jarmay K, Karakcsony G, Ozvar Z et al. Assessment of histological features in chronic hepatitis c. Hepatogastroenterology 2002; 49:.229-243
Jarmay K, Karakcsony G, Ozvar Z et al. Assessment of histological features in chronic hepatitis c. Hepatogastroenterology 2002; 49: 239–243
Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513–1520.
Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995; 19: 1409–1417.
Muratori P, Muratori L, Stroffolini T, Pappas G, Terlizzi P, Ferrari R et al. Prevalence of non-organ specific autoantibodies in HCV-infected subjects in the general population. Clin Exp Immunol. 2003; 131: 118–121
Gregorio GV, Pensati P, Iorio R, Vegnente A, Mieli-Vergani G, Vergani D. Auto-antibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol. 1998; 112: 471–86
Carrion AF, Martin P. Viral hepatitis in the elderly. Am J Gastroenterol. 2012; 107(5): 691–697.
Wasmuth H, Stolte C, Geier A, Dietrich C, Gartung C, Lorenzen J, Matern S, Lammert F. The presence of non-organ specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infec Dis 2004–... (access; …)
Cielecka-Kuszyk J, Komorowski M, Godzik P, Jablonska J, Madalinski K. Non organ specific and parietal cell autoantibodies n chronic liver diseases evaluated in the National Institute of Hygiene. E&C Hepatology 2011; 7(91–2): 39–43
Badiani RG, Becker V, Perez RM et al. Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis? WJG. 2010; 16(29): 3704–3708.
McFarlane IG, Smith HM, Johnson PJ, Bary GP, Vergani D, Wiliams R. Hepatitis C virus antibodies in chronic active hepatitis: Pathogenetic factors or false-positive result? Lancet 1990; 335: 754–757.
Lunel F, Abuf N, Franguel F. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 1992; 1: 359–364.
Fallahi P, Ferri C, Ferrari SM, Corrado A, Sansonno D, Antonelli A. Cytokines and HCV-related disorders. Clin Develop Immunol. 2012.
Herzog D, Yamato A, Jara P, Maggiore G, Sarles J, Alvares F. Sera of children with hepatitis C infection and Anti-Liver-Kidney Microsome-1 Antibodies recognize different CYP2D6 epitopes than adults with LKM+/HCV+ sera. J Pediatr Gastroenterol Nutr. 1999; 29(5): 551–555.
Karlsen AE, Dyrberg T. Molecular mimicry between non-self, modified self and self in autoimmunity. Semin Immunol. 1998; 10: 25–30.
Gregorio GV, Ghoudhuri K, Ma Y. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. C; In Exp Immunol. 2003; 133: 404–413
Gregorio GV, Ghoudhuri K, Ma Y, Vegnente A, Vergani GM, Vergani D. Mimicry between the hepatitis B virus DNA polymerase and the hepatitis B virus infection. J Immunol. 1999; 162: 1802–1810.
Cusick M, Libbey JE, Fuijinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allery Immunol. 2012; 42(1): 102–111.